The BIEM Verification Study: Experienced Venture Capitalists Assess a Biopharmaceuticals Innovation Expertise Model
Requires Subscription or Fee PDF

Keywords

BIEM model
Bioenterprise Innovation Expertise Model
entrepreneurial model testing
business model testing
biopharmaceutical failure
biopharmaceutical success

Abstract

Developing biopharmaceutical therapies is a scientifically complex endeavor, requiring from ten to fifteen years of effort with successive rounds of increasingly greater investment capital in a risk-intensive landscape. With failure rates at 88%, and an all-attempts-averaged investment of over $2B per approved drug, discussions of what leads to success and/or failure are pervasive. In this milieu, the BIEM (Bioenterprise Innovation Expertise Model) model was developed so that the status of a bioenterprise could quickly be assessed. Assessing the BIEM model, 20 biopharmaceuticals venture capitalists with 30 years average biotechnology industry experience, all having board experience, most having served as board chairs, and 80% having been CEO’s and/or presidents, rated the innovation expertise disciplines of BIEM 2.0 as to their importance in the scientific discovery through market-ready product innovation phase of biopharmaceutical development. Despite a small sample size, statistically significant insights were produced, verifying the BIEM model. The most important innovation expertise disciplines were intellectual property, science, regulatory expertise, and venture capital, in that order. Further, the strongest correlations linked regulatory expertise and science, and equally so, intellectual property and venture capital. Additional insights with respect to the profiles of the biopharmaceutical venture capitalists themselves is also presented.
https://doi.org/10.5912/jcb749
Requires Subscription or Fee PDF

References

P&S Market Research Report. (2015). Global Biopharmaceuticals market Size, Share, Development, Growth and Demand Forecast to 2020 – Industry Insights by Type (Monoclonal Antibodies, Recombinant Proteins, Interferon, Colony-Stimulating Factor, Erythopoietin, Recombinant Human Insulin, Vaccines, Growth Hormones, Infectious Diseases, Metabolic Disorders, Neurological Disorders, Cardiovascular Diseases and Others) Report Code HC1174. Retrieved June 12, 2016, from - https://www.psmarketresearch.com/marketanalysis/biopharma ceuticals-market

DiMasi J.A., Grabowski H.G. and Hansen R.A. (2016). Innovation in the pharmaceutical industry: new estimates of R&D costs. Journal of Health Economics, 47:20-33.

Yang, W. (2016). 2015 – another banner year for biotech. Nature Biotechnology, 34:127.

Giniatullina, A., Boorsma, A., Mulder, G.J. and van Deventer, S. (2013) Building for big pharma. Nature Biotechnology 31:284-287, doi:10.1038/nbt.2583.

Kruse, S., Slomiany, M., Bitar, R., Jeffers, S. and Hassan, M. (2014) Pharmaceutical R&D productivity: the role of alliances. Journal of Commercial Biotechnology 20(2): 12-20.

Czerepak, E. & Ryser, S. (2008) Drug approvals and failures: Implications for alliances. Nature Reviews Drug Discovery. 7(3): 197–198.

Gunn, M.A., Dever, J., Tzagarakis-Foster, C., Lorton, P., Kane, K. and Masterson, N. (2013). An agile, cross-discipline model for developing bio-enterprise professionals. Journal of Commercial Biotechnology, 19(4):72-87.

Sacks, L.V. et al. (2014) Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012. JAMA: the journal of the American Medical Association 311(4): 378–384.

FDA. (2016) New Drugs at FDA: CDER’s New Molecular Entitities and New Therapeutic Biological Products. Food and Drug Administration. Retrieved June, 26, 2016 from http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ DrugInnovation/ucm20025676.htm

Wang, B., Avorn, J. and Kesselheim, A. (2013) Clinical and regulatory features of drugs not initially approved by the FDA. Clinical Pharmacology and Therapeutics. 94(6): 670–677.

Schueler, J. and Ostler, T. (2016) Biopharmaceutical Startup’s Need for Regulatory Intelligence. Journal of Commercial Biotechnology 22(1): 6-14.

Ringel, M., Tollman, P., Hersch, G. & Schulze, U. (2013) Does size matter in R&D productivity? If not, what does? Nature Reviews Drug Discovery 12(12): 901–902.

Gunn, M. (2007) Welcome to BioTech Nation: My Unexpected Odyssey into the Land of Small Molecules, Lean Genes, and Big Ideas. New York: AMACOM.

Gunn, M. & Lorton, P. (2014) Measuring the Effectiveness of Global Immersive Study Tours to Attract Non-Scientific Working Professionals to the Bio-Enterprise. Technology Transfer and Entrepreneurship, 1(2): 117-131.

Siconolfi, M., Weaver, C. & Carreyrou, J. (2016, June 13). Walgreen’s Terminates Partnership With Blood-Testing Firm Theranos. The Wall Street Journal. Retrieved June 26, 2016 from http://www.wsj.com/articles/walgreen-terminates-partnership-with-blood-testing-firm-theranos-1465777062

Weaver, K.M., Liguori, E.W. and Vozikis, G.S. (2011), Entrepreneur business climate perceptions: Developing a measure and testing a model, Journal of Applied Business and Economics, 12,(1): 95-104.

Hansen, D.J., Lumpkin, G.T. and Hills, G.E. (2011), A multidimensional examination of a creativity-based opportunity recognition model. International Journal of Entrepreneurial Behaviour and Research 17(5): 515-533.

Antoncic, B. and Hisrich, R.D. (2004), Corporate entrepreneurship contingencies and organizational wealth creation, The Journal of Management Development, 23(5-6): 518-549.

Kaufman, J.C., Baer, J., Cole, J.C., and Sexton, J.D. (2008), A comparison of expert and non-expert raters using the consensual assessment technique, Creativity Research Journal, 20( 2): 171-178.

Holthausen, R.S., Wisdom, M.J., Pierce, J., Edwards, D.K., and Rowlands, M.M. (1994) Using Expert Opinion to Evaluate a Habitat Effectiveness Model for Elk in Western Oregon and Washington, United States Dept. of Agriculture, Research paper PNW-RP-479.

MacCallum, R.C. and Widaman, K.F. (1999) Sample size in factor analysis.Psychological Methods 4(1): 84-99.

Hair Jr., J.F., Black, W.C. Babin, B.J. and Anderson, R.E. (2010) Multivariate Data Analysis, 7th edition. Upper Saddle River, NJ: Prentice Hall.

De Winter, J.C.F., Dodou, D. and Wieringa, P.A. (2009) Exploratory factor analysis with small sample sizes, Multivariate Behavioral Research, 44: 147-181.

Geoff Norman (2010) Likert scales, levels of measurement and the ‘laws’ of statistics. Advances in Health Sciences Education: Theory and Practice 15(5): 625-32.

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.